Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from AstraZeneca
Buses will be available from the Hyatt Regency Orlando to the Hilton Orlando and back for all registrants
Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder Cancers is a live symposium to be held adjunct to the 2017 ASCO-SITC Immuno-Oncology Symposium, Online Learning Continuum, & Reminder Series in Orlando, Florida. The speed at which information about immunotherapies for cancer is emerging has raised questions about how best to incorporate them into state-of-the-art patient care plans. Lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer are tumor types for which some of the most exciting progress has been made. Immune-based approaches are likely to continue to alter treatment paradigms for these cancers for which significant unmet clinical needs remain. The inaugural annual ASCO-SITC Clinical Immuno-Oncology Symposium is the perfect venue for programming that is designed to provide clinical context for noteworthy evidence on these tumor types. This program is geared to meet the needs of busy researchers and clinicians who strive to advance the management for patients with these tumors.
Key topics on the agenda include:
- Methods to optimize the use of biomarkers in immuno-oncology;
- Strategies to use novel compounds as monotherapy and how to rationally combine modalities to build on improved outcomes; and
- Treatment-related toxicity management, particularly important as immuno-oncology combinations are investigated and since proactively mitigation of these is critical to minimize their impact on outcomes
- ASCO-SITC 2017 Meeting Preview
Upon completion of this activity, participants will be able to:
- Explain clinically unmet needs in the management of non-small cell lung cancer, head and neck squamous cell carcinoma (HNSCC), and bladder cancer
- Describe how the immune system can be harnessed to treat cancer and the mechanistic rationale for the application of checkpoint inhibition strategies to target specific solid tumors
- Interpret recent findings from clinical trials conducted with immuno-oncology strategies for the treatment of lung cancer, HNSCC, and bladder cancer
- Describe the current status of biomarkers as a method to personalize care with the use of immuno-oncology strategies
- Evaluate methods to mitigate treatment-related toxicities via proactive mitigation and management of immune-related adverse events (irAEs)
This educational activity is directed toward medical oncologists and fellows who treat patients with cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals will be invited to participate.
Feb 28, 2017
Cancer Summaries and Commentaries™: Updates from Singapore: Advances in Personalized Lung Cancer Treatment
Feb 28, 2017